Piper Sandler began coverage on shares of aTyr Pharma (NASDAQ:LIFE) in a research note published on Tuesday morning, Price Targets.com reports. The brokerage issued an overweight rating and a $19.00 price objective on the biotechnology company’s stock. Piper Sandler also issued estimates for aTyr Pharma’s Q3 2021 earnings at ($0.60) EPS, Q4 2021 earnings at ($0.44) EPS, FY2021 earnings at ($2.15) EPS, Q1 2022 earnings at ($0.44) EPS, Q2 2022 earnings at ($0.48) EPS, Q3 2022 earnings at ($0.48) EPS, Q4 2022 earnings at ($0.52) EPS and FY2022 earnings at ($1.92) EPS.
Several other research analysts have also weighed in on the company. Oppenheimer upped their price target on aTyr Pharma from $14.00 to $20.00 and gave the company an outperform rating in a research report on Tuesday, September 14th. Zacks Investment Research lowered aTyr Pharma from a hold rating to a strong sell rating in a research report on Friday, August 13th. Roth Capital upped their target price on aTyr Pharma from $20.00 to $21.00 and gave the stock a buy rating in a research report on Monday, September 13th. Jonestrading reaffirmed a buy rating and issued a $15.00 target price on shares of aTyr Pharma in a research report on Wednesday, June 30th. Finally, HC Wainwright upped their target price on aTyr Pharma from $13.00 to $18.00 and gave the stock a buy rating in a research report on Monday, September 13th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat, aTyr Pharma presently has an average rating of Buy and a consensus price target of $16.50.
Shares of LIFE opened at $10.25 on Tuesday. aTyr Pharma has a 52-week low of $2.93 and a 52-week high of $13.10. The firm has a market cap of $173.43 million, a price-to-earnings ratio of -4.46 and a beta of 2.00. The business’s 50 day moving average is $5.99 and its two-hundred day moving average is $4.98.
In related news, Director Paul Schimmel bought 250,000 shares of the company’s stock in a transaction dated Monday, September 20th. The stock was acquired at an average cost of $8.00 per share, with a total value of $2,000,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 5.14% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Susquehanna International Group LLP acquired a new stake in aTyr Pharma during the 2nd quarter valued at $53,000. XTX Topco Ltd acquired a new stake in aTyr Pharma during the 2nd quarter valued at $60,000. Citadel Advisors LLC acquired a new stake in aTyr Pharma during the 1st quarter valued at $60,000. Northern Trust Corp increased its holdings in aTyr Pharma by 18.5% during the 2nd quarter. Northern Trust Corp now owns 26,105 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 4,072 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in aTyr Pharma during the 2nd quarter valued at $148,000. 40.89% of the stock is owned by institutional investors and hedge funds.
About aTyr Pharma
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel immunological pathways. Its product pipeline include ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1;DARS-1(3). The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.